Identifying blood markers for malignant pancreatic lesions
Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions.
This study is trying to find blood markers that can help tell the difference between cancerous and non-cancerous pancreatic growths in patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Besancon Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Besançon and 1 other locations) |
| Trial ID | NCT06397846 on ClinicalTrials.gov |
What this trial studies
This study aims to identify plasma biomarkers that can differentiate between malignant and benign pancreatic lesions. By analyzing biological samples from patients with benign pancreatic conditions, the research seeks to develop a clinico-biological signature that enhances the diagnosis and treatment of pancreatic cancer. The study will initially focus on candidate biomarkers identified in preliminary work, with the possibility of exploring additional markers. The ultimate goal is to improve diagnostic accuracy and therapeutic management for patients at risk of pancreatic cancer.
Who should consider this trial
Good fit: Ideal candidates are men and women aged 18 and older who are being monitored for benign pancreatic lesions.
Not a fit: Patients with a known malignant pancreatic tumor will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of a blood test that improves early detection and treatment of pancreatic cancer.
How similar studies have performed: Other studies have explored biomarkers for pancreatic cancer detection, but this specific approach focusing on the tumor stroma is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women ≥18 years * Patient followed for benign pancreatic lesions: chronic pancreatitis acute pancreatitis at a distance from the acute episode (\> 4 weeks) with indication for echo-endoscopy for suspected precancerous pancreatic lesions (PanIN, TIPMP, mucinous cystadenomas) or other cystic lesions (serous cystadenomas) Exclusion Criteria: * Malignant pancreatic tumor * Legal incapacity or limited legal capacity
Where this trial is running
Besançon and 1 other locations
- University Hospital of Besancon — Besançon, France (Recruiting)
- Hôpital Nord Franche-Comté — Montbéliard, France (Recruiting)
Study contacts
- Study coordinator: Angélique VIENOT, Dr
- Email: a3vienot@chu-besancon.fr
- Phone: +3381479999
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.